Journal article
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma
G Chong, FT Lee, W Hopkins, N Tebbutt, JS Cebon, AJ Mountain, B Chappell, A Papenfuss, P Schleyer, P U, R Murphy, V Wirth, FE Smyth, N Potasz, A Poon, ID Davis, T Saunder, GJ O'Keefe, AW Burgess, EW Hoffman Show all
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2005
Abstract
Purpose: Humanized monoclonal antibody A33 (huA33) targets the A33 antigen which is expressed on 95% of colorectal cancers. A previous study has shown excellent tumor-targeting of iodine-131 labeled huA33 (131I-huA33). Therefore, we did a phase I dose escalation trial of 131I-huA33 radioimmunotherapy. Experimental Designs: Fifteen patients with pretreated metastatic colorectal carcinoma each received two i.v. doses of 131I-huA33. The first was an outpatient trace-labeled "scout" dose for biodistribution assessment, followed by a second "therapy" dose. Three patients were treated at 20, 30, and 40 mCi/m2 dose levels, and six patients at 50 mCi/m2 to define the maximum tolerated dose. Results:..
View full abstract